Avenzo Therapeutics Partners with DualityBio for Innovation in Cancer Treatment

Avenzo Therapeutics and DualityBio Announce Licensing Agreement

Avenzo Therapeutics, a pioneering biotechnology firm focused on oncology, has recently forged a remarkable partnership with Duality Biotherapeutics to enhance the development of next-generation cancer therapies. This collaboration aims specifically at the commercialization of a promising EGFR/HER3 bispecific antibody-drug conjugate (ADC), known as AVZO-1418/DB-1418. This agreement underscores both companies' commitment to innovation in the realm of cancer treatment.

Details of the Exclusive License Agreement

Under the newly established exclusive licensing agreement, Avenzo Therapeutics will be responsible for the development, manufacturing, and global commercialization, except for Greater China, of the AVZO-1418/DB-1418 compound. This initiative is expected to bring significant benefits to the treatment of various solid tumors, enhancing the existing options available in the oncology space.

As part of this agreement, DualityBio will initially receive a substantial upfront payment of $50 million. In addition to this, there are prospects for further compensation that may total around $1.15 billion through various development, regulatory, and commercial milestones. DualityBio will also be eligible to receive royalties based on the sales generated in the territories covered by Avenzo.

Insights from Executive Leadership

In a statement regarding this collaboration, Athena Countouriotis, M.D., the Co-founder, President, and CEO of Avenzo, highlighted the promising potential of this drug candidate, particularly in addressing a range of solid tumors. The unique design of AVZO-1418/DB-1418 targets both the EGFR and HER3 receptors, which could lead to greater clinical efficacy compared to existing treatment options. This partnership aims to expedite the process of moving AVZO-1418/DB-1418 into clinical trials, enhancing the therapeutic landscape for patients facing the challenges of cancer.

John Zhu, Ph.D., Founder and CEO of DualityBio, expressed enthusiasm about the shared vision between the organizations. He affirmed that the collaboration is aimed at tackling significant unmet needs in oncology by leveraging advanced biotherapeutic techniques. The two firms are optimistic that their combined efforts will culminate in improved treatment alternatives for cancer patients.

Ongoing Development and Future Goals

Currently, Avenzo is conducting IND-enabling studies with a view to initiating a first-in-human clinical study of AVZO-1418/DB-1418 within the near future. The collaborative endeavor focuses intensively on establishing a robust clinical pipeline that provides innovative solutions to the oncology sector.

About AVZO-1418/DB-1418

AVZO-1418/DB-1418 represents a dual-targeting approach that effectively harnesses the capabilities of a topoisomerase-1 inhibitor-based ADC. Utilizing DualityBio’s cutting-edge DIBAC (Duality Innovative Bispecific Antibody Conjugate) platform, this drug candidate has demonstrated superior binding affinity towards tumor cells in preclinical studies. It showcases substantial potential efficacy against a variety of solid tumors, including those that exhibit resistance to traditional treatments.

About Avenzo Therapeutics

Avenzo Therapeutics is committed to developing groundbreaking oncology therapies. Their leading candidate, AVZO-021, represents an innovative, highly potent, and selective inhibitor of CDK2, integral to cell cycle regulation. Avenzo is currently exploring this candidate in a Phase 1 clinical study to assess its effectiveness in treating advanced solid tumors and in combination therapies for specific breast cancer subtypes.

About DualityBio

Duality Biotherapeutics is dedicated to the discovery and development of novel ADCs directed at both cancer and autoimmune diseases. With numerous advanced ADC technology platforms backed by global intellectual property rights, DualityBio continues to expand its pipeline while actively engaging in clinical trials worldwide. The company is on track to provide innovative therapeutic options through strategic collaborations and the ongoing development of various ADC candidates.

Frequently Asked Questions

What is the main focus of the partnership between Avenzo and DualityBio?

The partnership aims to develop and commercialize AVZO-1418/DB-1418, a bispecific antibody-drug conjugate targeting EGFR and HER3 for cancer treatment.

What is AVZO-1418/DB-1418?

AVZO-1418/DB-1418 is an investigational therapy designed to target both the EGFR and HER3 receptors, which could enhance treatment outcomes for various solid tumors.

What financial aspects are involved in this agreement?

DualityBio will receive an upfront payment of $50 million plus potential milestone payments totaling around $1.15 billion and tiered royalties on sales.

What stage of development is AVZO-1418/DB-1418 currently in?

IND-enabling studies are ongoing with plans to progress it into first-in-human clinical trials soon.

What other therapies does Avenzo Therapeutics offer?

Avenzo is working on AVZO-021, a CDK2 inhibitor, which is in Phase 1 studies for advanced solid tumors and specific breast cancer treatments.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.